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Rapidly growing cancer cells need cholesterol to generate new
cell membranes. It has been demonstrated that cancer cells show
an increased uptake of low-density lipoprotein (LDL).1,2 Blood
cholesterol level in cancer patients has been found to be lower than
in normal subjects.1,3 LDL is the major cholesterol carrier in
plasma, and its uptake is mediated by the LDL-receptor (LDL-R),
a glycoprotein overexpressed on the surface of cancer cells.
Apolipoprotein B on the LDL particles can be recognized by LDL
receptor and medicates the endocytosis of LDL into cytosol.4
Cholesterol is released by the hydrolysis of cholesterol esters in
the LDL. Based on this process, it seems that cholesterol can be
used as a delivery agent to enhance the selective penetration of
anti-cancer drugs into cancer cell cytosol via LDL-receptor. It has
been reported that cholesterol non-covalent conjugated with
chemo agent platinum enhanced the cancer cell uptake.5,6 However, the stability of the non-covalent conjugate makes the application of this novel strategy difficult.
Herein, we report a cholesterol and chemo agent conjugate via
covalent bond, and the covalent bond is designed to be hydrolyzed
by the liposomal digestive enzymes. Histone deacetylase (HDAC)
inhibitor Vorinostat (SuberAniloHydroxamic Acid, SAHA) was used

as the parental compound to design the cholesterol conjugate
(Fig. 1).
HDAC inhibitors are a class of promising multi-functional anticancer agents.7–9 These agents are able to regulate the gene transcription via chromatin remodeling, eventually modulating a variety of cellular functions including proliferation, differentiation, and
apoptosis. The multiple-functional characteristics contribute to
their strong anti-cancer potency across a wide range of hematologic malignancies.7 Vorinostat, the first HDAC inhibitor approved
by FDA in 2005, has been well used in clinic for cancer treatment.10
To conjugate cholesterol into SAHA, an amino group was introduced on the 40 position of the aromatic ring of the compound in
order to conveniently form the designed amide bond. It has been
reported that 4-amino SAHA showed anti-proliferative activity
comparable to SAHA.11 The synthesis of the conjugate is illustrated
in Scheme 1. Our hypothesis is that the carbamate of the conjugate
could be hydrolyzed by the liposomal lipase, which is a process
similar to the hydrolysis of cholesteryl esters. The decarboxylation
will follow after the hydrolysis and a carbon dioxide molecule will
be released, which will generate 4-amino SAHA and cholesterol.
It has been reported that the carbamate group could be hydrolyzed by liver or plasma digestive enzymes.12 After the synthesis of
the conjugate, it is necessary to determine if the carbamate group
between cholesterol and 4-amino-SAHA could be hydrolyzed by
the enzymes in the cytosol. As illustrated in Fig. 2, 4-amino-SAHA

Fig. 1. Cholesterol conjugated with SAHA.

in cell lysate was examined with LC–MS/MS, which is shown in the
left panel of Fig. 2. Due to the complex components of cell lysate,
the experiment was performed with a 5500 Q-TRAP triple quadru-

pole, tandem mass spectrometer coupled with an Electrospray
Ionizer. 4-amino-SAHA was added in the H292 cancer lysate and
incubated at 37 °C for 30 min. After protein precipitation with acetonitrile, the sample was directly used for the experiment to
develop a method for the detection of the compound (upper panel
of Fig. 2). Consequently, the conjugate was incubated with the
same fresh cell lysate for 30 min, and the generated 4-amino-SAHA
was detected with the same method to check if the conjugate could
be hydrolyzed by the enzymes in the cell lysate (low panel of
Fig. 2). The signal was weak due to the low amount of 4-aminoSAHA from the hydrolyzed conjugate. There are three possibilities
for the low amount of generated 4-amino-SAHA. First, the lysing
process may damage the digestive enzymes in the lysosomes and
the enzyme catalytic capability is harmed. Second, the carbamate
group between the cholesterol and 4-amino-SAHA cannot be recognized by the digestive enzyme very well. Third, the carbamate

Scheme 1. Synthesis of the cholesterol conjugated SAHA.

Fig. 2. Hydrolysis of the conjugate by the cancer cell lysate. The conjugate was incubated with H292 cancer cell lysate at 37 °C for 30mins. After protein precipitation, the
generated 4-amino-SAHA was determined with LC–MS/MS(5500 Q-TRAP triple quadrupole, tandem mass spectrometer (AB Sciex, Toronto, Canada)coupled with an
Electrospray Ionizer (Framingham, Massachusetts, USA) and interfaced with High Performance Liquid Chromatography).

group is much more stable than the ester bond and cannot be
effectively hydrolyzed by the enzymes. Nevertheless, the results
demonstrate that the conjugate could be hydrolyzed by the digestive enzymes in the cytosol, although the efficiency needs some
improvement in the future. The conjugate is still a good tool for
us to test our hypothesis of the 4-amino-SAHA delivery.
Consequently, the conjugate was loaded into LDL particles via
sonication. Commercially available LDL shows a diameter about
48 nm (Fig. 3). After sonication, the broken LDL particles were reformed into new particles overnight, and the new particle size
was much bigger than the original particles and reached a diameter about 164 nm. When the conjugate was introduced during the
sonicating and re-forming process, the newly formed particle size
was similar to the vehicle control group with a diameter of
171 nm. The direct evidence of the conjugate loaded into the particles is the aqueous solubility of the conjugate. Before loading into
the LDL particles, the conjugate significantly precipitated in aqueous solution at 20 lM. However, the conjugate loaded into LDL did
not show any precipitation even at 500 lM in aqueous solution.
When the conjugate was introduced into the LDL solution without
sonication, the size of the particles was also dramatically increased
to 193 nm, which was actually due to the precipitation of the conjugate in aqueous solution. The precipitated conjugate interacted
with the LDL and formed large aggregated particles.

Particles

To check the biological activity of the compounds and the LDL
particles containing the conjugate, these compounds were tested
with H292 lung cancer cell proliferation assay. First, the inhibitory
effect of these compounds to the growth of cancer cells without
LDL as the delivery vehicle was determined. The results exhibited
that SAHA and amino-SAHA inhibited cancer cell growth with similar IC50s at sub micromolar levels, which is consistent with the
other study.11 The conjugate did not show any inhibition to the cell
growth, and it significantly precipitated in the cell culture medium
during the treatment even at 20 lM (Fig. 4). The results suggest
that the conjugate cannot get into the cells directly without LDL
as the vehicle.
Next, the cells were treated with the compounds plus LDL
without sonication, and the control was DMSO and same amount
of LDL in the treatment. It should be noted that SAHA and aminoSAHA showed similar activity in inhibiting cancer cell growth,
which is consistent to the treatment without LDL (Fig. 5). The
results suggest that the LDL did not affect the activity of the SAHA
and amino-SAHA. The conjugate still significantly precipitated in
the cell culture medium even at 20 lM and did not show inhibitory effect to the cell growth, which was actually expected. This
was because the conjugate was just mixed together with the
LDL without sonication and it was not loaded into the LDL
particles.

Diameter of Non-sonicated
(nm ± SD)

LDL
Amino-SAHA-Cholesterol
conjugate with LDL
Amino-SAHA with LDL

Diameter of Sonicated
(nm ± SD)

47.6 ± 0.5

164.0 ± 0.9

193.4 ± 4.2

170.5 ± 2.4

50.4 ± 0.4

182.5 ± 3.6

Fig. 3. LDL particle size was determined in PBS by dynamic light scattering (DLS).

IC50 values
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Fig. 4. Growth inhibitory effects of the compounds on H292 cells. The cells were treated with DMSO or the compounds for 72 h. Cell viability was measured by MTT assay.
The treatments were quadruplicated and repeated three times.
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Fig. 5. Growth inhibitory effects of the compounds mixed with LDL on H292 cells. H292 cells were treated with DMSO plus LDL and the compounds for 72 h. Cell viability was
measured by MTT assay. The treatments were quadruplicated and repeated three times.

Treatment (LDL + compound
was sonicated and re-formed)
SAHA + LDL
Amino-SAHA-Cholesterol
conjugate + LDL
Amino-SAHA + LDL

IC50 values
(µM ± SD)
4.61 ± 2.98
>500
14.65 ± 8.90

depleted FBS was used to repeat the last experiment and the
results are listed in Fig. 7.
SAHA and amino-SAHA inhibited the cell growth with IC50s at
sub micromolar concentrations, which are similar to the results
in Fig. 6. The conjugate showed significantly improved activity to
inhibit cell growth with an IC50 of 91.22 lM compared to the
results in Fig. 6. The results indicate that the cells did recognize
the reformed LDL particles, and the conjugate was delivered into
cells and inhibited cell growth. However, the activity of the conjugate was not as high as the amino-SAHA, suggesting that the delivery efficacy was not good enough to be comparable to the passive
penetration of free amino-SAHA. This could be due to the low
hydrolysis efficiency of the carbamate group as well. Nevertheless,
if the cancer cell uptake and conjugate hydrolysis can be improved,
this conjugation is a feasible strategy to enhance the selective
delivery of chemotherapeutical agents into cancer tissue.
In summary, our findings indicate that cholesterol conjugated
SAHA could be up-taken by cancer cells via LDL receptor after loading into LDL particles. Due to the increased LDL receptor in cancer
cell surface, this strategy has the potential to increase the selectiv-

Cell Viability(% of control)

Subsequently, the cells were treated with LDL combination with
the compounds after sonication. The reformed particles were much
bigger than the original LDL particles as exhibited in Fig. 3. The
control was DMSO plus LDL after sonicating and re-forming. SAHA
and amino-SAHA also showed similar activity in inhibiting cancer
cell growth. The results suggest that SAHA and amino-SAHA can
effectively penetrate into the cells and inhibit cell growth regardless of the LDL (Fig. 6). Due to their good solubility, these compounds are less likely to be loaded into the LDL particles via
simple sonicating process. So they mainly enter the cells in free
drug form via passive diffusion to show their activity. The conjugate did not precipitate in the cell culture medium even at
500 lM, suggesting that the conjugate was loaded into the particles. To our surprise, the conjugate did not show inhibitory effect
to the cell growth (Fig. 6).
We speculate that the low activity of the conjugate may be due
to the low cellular uptake of the new LDL particles. Regular fetal
bovine serum (FBS) that is rich in LDL was used for the assay,
and the LDL particles may compete with our conjugate loaded
LDL particles for LDL receptor. To confirm the hypothesis, LDL
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Fig. 6. Growth inhibitory effects of the compounds loaded into LDL on H292 cells. H292 cells were treated for 72 h. Cell viability was measured by MTT assay. The treatments
were quadruplicated and repeated three times.
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Treatment (LDL + compound
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with LDL depleted FBS
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Fig. 7. Growth inhibitory effects of the compounds loaded into LDL on H292 cells with LDL depleted FBS. H292 cells were treated for 72 h. Cell viability was measured by MTT
assay. The treatments were quadruplicated and repeated three times.

ity of a chemotherapeutical agent to cancer tissue than normal tissue that has relatively lower LDL receptor. Further research into
other chemo agents conjugated with cholesterol and the loading
efficacy of the conjugate into LDL with a more quantitative method
are still undergoing.
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